Autopsy report · NCT02514031

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The study placed on temporarily hold to enrollment due to quality testing necessary for the study drug.”

The sponsor’s own words in the registry.

Life of this trial

Registered 9 months before it started.
Ran for about 6 years 2 months before it stopped.
17 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: University of Texas Southwestern Medical Center
Sponsor type: University, hospital or other
Conditions: Pancreatic Cancer
Interventions: ARQ-761; Gemcitabine; nab-paclitaxel
Participants: 17
Sites: 2
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.